Skip to content
Peptigraph home

ACHIEVE-1: Orforglipron Phase 3 trial (NCT05971940)

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
559
actual
Start
9 Aug 2023 (actual)
Primary completion
3 Apr 2025 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT05971940 study arms
ArmTypeInterventionsDescription
PlaceboPlacebo comparatorDrug: PlaceboParticipants received once daily (QD) doses of orforglipron-matching placebo capsules administered orally, over a period of 40 weeks.
3 mg OrforglipronExperimentalDrug: OrforglipronParticipants received orforglipron capsules administered orally QD, starting at 1 milligram (mg) and increasing by 1 mg every 4 weeks until reaching a targeted dose of 3 mg, which was then maintained up to week 40.
12 mg OrforglipronExperimentalDrug: OrforglipronParticipants received orforglipron capsules administered orally QD, starting at 1 mg and increasing every 4 weeks until reaching a targeted dose of 12 mg, which was then maintained up to week 40.
36 mg OrforglipronExperimentalDrug: OrforglipronParticipants received orforglipron capsules administered orally QD, starting at 1 mg and increasing every 4 weeks until reaching a targeted dose of 36 mg, which was then maintained up to week 40.
Endpoints

Primary endpoint

NCT05971940 primary outcomes
MeasureTime frame
Change From Baseline in HbA1cBaseline, Week 40
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05971940 secondary outcomes
MeasureTime frame
Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)Week 40
Percentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol)Week 40
Change From Baseline in Fasting Serum Glucose (FSG)Baseline, Week 40
Percent Change From Baseline in Body WeightBaseline, Week 40
Change From Baseline in Body WeightBaseline, Week 40
Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) CholesterolBaseline, Week 40
Percent Change From Baseline in TriglyceridesBaseline, Week 40
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG)Baseline, Week 40
Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight ReductionWeek 40
Change From Baseline in Systolic Blood Pressure (SBP)Baseline, Week 40
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) ScoresBaseline, Week 40
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05971940.

ACHIEVE-1 in early type 2 diabetes treated with diet and exercise

Participants were randomised 1:1:1:1 to orforglipron 3, 12 or 36 mg or placebo once daily for 40 weeks, and had an HbA1c of 7.0% to 9.5%.[2]

HbA1c fell by 1.24, 1.47 and 1.48 points on 3, 12 and 36 mg against 0.41 on placebo.[2]

Body weight changed by -4.5%, -5.8% and -7.6% across the orforglipron arms and -1.7% on placebo.[2]

Permanent discontinuation due to adverse events occurred in 4.4 to 7.8% of orforglipron recipients and 1.4% of placebo recipients.[2]

Sources

  1. 1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544435Accessed 2 Oct 2026

Found an error? Report a correction.